Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
Healthcare
$39.15 +8.79%
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
52W Low $23.00High $36.61
Volume 0.30M
Average 0.34M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$61.48M
FY 2025 · Annual
Investing Cash Flow
-$81.48M
FY 2025 · Annual
Financing Cash Flow
$156.30M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (63.91M) |
| Depreciation & Amortization | 304K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.01M |
| Change in Working Capital | 1.36M |
| Accounts Receivables | 0 |
| Inventory | 0 |
| Accounts Payables | 2.58M |
| Other Working Capital | (1.22M) |
| Other Non-Cash Items | (1.23M) |
| Operating Cash Flow | (61.48M) |
| Capital Expenditures | (16K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (252.5M) |
| Sales of Investments | 171.03M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (81.48M) |
| Debt Repayment | (120K) |
| Common Stock Issued | 0 |
| Common Stock Repurchased | 0 |
| Dividends Paid | 0 |
| Other Financing Activities | 0 |
| Financing Cash Flow | 156.3M |
| Effect of Forex Changes | 223K |
| Net Change in Cash | 13.57M |
| Free Cash Flow | (61.49M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$63.9M
+ D&A$304.0K
+ Stock-Based Comp$2.0M
+ Deferred Tax$0
+ Working Capital$1.4M
- Other Non-Cash-$1.2M
= Operating Cash Flow-$61.5M
- Capex-$16.0K
= Free Cash Flow-$61.5M
Analysis
FY2025 free cash flow is -$61.5M. FCF conversion is 96.2% of net income. Operating cash flow was -$61.5M, with capex of -$16.0K. The largest bridge item is Stock-Based Comp at $2.0M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 | |
| 3 | Initial statement of beneficial ownership | Sep 25, 2026 |
Does COAG generate free cash flow?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) generated -$61.49M of free cash flow in fiscal 2025.
How much operating cash flow does COAG produce?
Operating cash flow was -$61.48M, before capital expenditures of $16,000.00.
Continue the stock analysis
Jump to another research area for this company.